Table 3 Overview of severe thrombotic complications despite prophylaxis with enoxaparin and AT III
Patients with deep vein thrombosis | Location of thrombosis | Risk factors (hypertriglyceridemia, hyperleukocytosis, sepsis, adipositas, genetic) | Gender | Age at thrombosis [years] | Treatment received for thrombosis | Interruption of L-asparaginase during further therapy | Recurrence of deep vein thrombosis at a later date |
|---|---|---|---|---|---|---|---|
#1 | V. axillaris/sub-clavia sinistra | no | male | 7.35 | Unfractionated heparin via perfusor for 5 days, then switch to enoxaparin twice daily in therapeutic dose for 12 days, after that once daily | no | no |
#2 | Sinus vein | no | female | 3.27 | Unfractionated heparin via perfusor for 5 days, then switch to enoxaparin twice daily in therapeutic dose until recanalization of sagittal sinus after 8 weeks | no | no |
#3 | Vv. iliacae internae | Massive hypertriglyceridemia, adipositas | male | 12.03 | Unfractionated heparin via perfusor (dose 20 IE/kg/h) for 14 days, then switch to enoxaparin twice daily in therapeutic dose | no | no |
#4 | V. fibularis sinistra | Heterozygous mutation FactorII (G20210A), homozygous MTHFR mutation (C677T) | male | 17.90 | Enoxaparin twice daily in therapeutic dose during whole intensive therapy, once daily during maintenance | no | no |
#5 | Vv. iliacae externae | no | male | 5.11 | Enoxaparin twice daily in therapeutic dose | no | no |